Literature DB >> 7516722

Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: steady-state pharmacokinetics in the rat.

A D McLeod1, L Tolentino, T N Tozer.   

Abstract

Chronic colitis, e.g., ulcerative colitis and Crohn's disease, is presently treated with glucocorticoids and other antiinflammatory agents. Side-effects limit chronic glucocorticoid therapy. The dose, and consequently the side-effects, may be reduced by using prodrugs that selectively deliver drug to the colon. We previously synthesized glucocorticoid-dextran conjugates in which dexamethasone was attached to dextran (weight-average molecular weight = 72,600) using dicarboxylic acid linkers (succinate and glutarate). In the present study, dexamethasone-succinate-dextran and dexamethasone-glutarate-dextran were administered to two groups of male Sprague-Dawley rats by intragastric infusion. In two additional groups, disodium dexamethasone phosphate and dexamethasone hemisuccinate were each administered by subcutaneous infusion. In a fifth group, dexamethasone was administered by intragastric infusion. All groups were infused for sufficient time for steady state to be achieved. Colon-specific delivery was quantified using a drug-delivery index (DDI) in which steady-state dexamethasone concentrations in the cecum and colon were compared with those measured in blood after separate administrations of dexamethasone and dexamethasone-dextran conjugate. The colonic DDI values for dexamethasone-succinate-dextran and dexamethasone-glutarate-dextran were approximately seven and four, respectively. These values were a result of higher tissue concentrations and lower blood concentrations of dexamethasone after intragastric administration of the conjugates compared to subcutaneous and intragastric administration of dexamethasone. The pharmacokinetics of methyl-prednisolone was also investigated after subcutaneous infusion. Observed cecal and colonic tissue-to-blood ratios of 19:1 and 12:1, respectively, showed that this drug is extensively delivered to the large intestine even after subcutaneous administration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516722     DOI: 10.1002/bdd.2510150207

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  5 in total

Review 1.  ["Targeted delivery" in the gastrointestinal tract].

Authors:  C S Leopold
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 2.  Endodontic-periodontal locally delivered antibiotics.

Authors:  Amela Lacević; Edina Vranić; Irfan Zulić
Journal:  Bosn J Basic Med Sci       Date:  2004-02       Impact factor: 3.363

3.  In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery.

Authors:  C S Leopold; D R Friend
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

4.  Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine.

Authors:  Inho Kim; Hyesik Kong; Younghyun Lee; Sungchae Hong; Jungoh Han; Sunhwa Jung; Yunjin Jung; Young Mi Kim
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

5.  Conjugation of metronidazole with dextran: a potential pharmaceutical strategy to control colonic distribution of the anti-amebic drug susceptible to metabolism by colonic microbes.

Authors:  Wooseong Kim; Yejin Yang; Dohoon Kim; Seongkeun Jeong; Jin-Wook Yoo; Jeong-Hyun Yoon; Yunjin Jung
Journal:  Drug Des Devel Ther       Date:  2017-02-14       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.